Open Access
J Oral Med Oral Surg
Volume 25, Number 1, 2019
Article Number 11
Number of page(s) 6
Section Article pédagogique / Educational article
Published online 22 February 2019
  1. Sibaud V, Vigarios E. Toxicités orales des thérapies ciblées anticancéreuses. Med Buccale Chir Buccale 2015;21:149–155. [CrossRef] [Google Scholar]
  2. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004;100(9 Suppl):1995–2025. [CrossRef] [PubMed] [Google Scholar]
  3. Stepkowski SM, Tian L, Napoli KL, Ghobrial R, Wang ME, Chou TC, et al. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection. Clin Exp Immunol 1997;108:63–68. [Google Scholar]
  4. Martins F, de Oliveira MA, Wang Q, Sonis S, Gallotini M, George S, et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 2013;49:293–298. [CrossRef] [PubMed] [Google Scholar]
  5. Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 2014;25:808–815. [CrossRef] [PubMed] [Google Scholar]
  6. Agbo-Godeau SN, Scotté F. Gestion des effets secondaires des thérapies ciblées dans le cancer du rein: effets secondaires stomatologiques (mucites, épistaxis). Bull Cancer 2011;98:117–126. [Google Scholar]
  7. Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017;25 (5):1713–1739. [CrossRef] [PubMed] [Google Scholar]
  8. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010;116 (1):210–215. [PubMed] [Google Scholar]
  9. Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012;17 (1):135–144. [CrossRef] [PubMed] [Google Scholar]
  10. Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S, Treister N. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 2013;49 (4):293–298. [CrossRef] [PubMed] [Google Scholar]
  11. Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, et al. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med 2016;5 (8):1897–1907. [Google Scholar]
  12. Bankvall M, Sjoberg F, Gale G, Wold A, Jontell M, Ostman S. The oral microbiota of patients with recurrent aphthous stomatitis. J Oral Microbiol 2014;6:25739. [CrossRef] [PubMed] [Google Scholar]
  13. Sonis S, Andreotta PW, Lyng G. On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)—studies using an organotypic model ofthe oral mucosa. Oral Dis 2017;23 (3):347–352. [CrossRef] [PubMed] [Google Scholar]
  14. Divers J, O'Shaughnessy J. Stomatitis associated with use of mTOR inhibitors: implications for patients with invasive breast cancer. Clin J Oncol Nurs 2015;19:468–474. [CrossRef] [PubMed] [Google Scholar]
  15. Porta C, Ostanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, et al. Management of adverse events associated with the use of évérolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011;47:1287–1298. [CrossRef] [PubMed] [Google Scholar]
  16. Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister M. Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors. Clin J Oncol Nurs 2011;15:E83–E89. [CrossRef] [PubMed] [Google Scholar]
  17. Cardona A, Balouch A, Abdul MM, Sedghizadeh PP, Enciso R. Efficacy of chlorhexidine for the prevention and treatment of oral mucositis in cancer patients: a systematic review with meta-analyses. J Oral Pathol Med 2017;46 (9):680–688. [CrossRef] [PubMed] [Google Scholar]
  18. de Oliveira MA, Martins Q, Wang S, Sonis S, Demetri S, George S, et al. Clinical presentation and management of mTOR inhibitor- associated stomatitis. Oral Oncol 2011;47:998–1003. [CrossRef] [PubMed] [Google Scholar]
  19. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, et al. Prevention of évérolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol 2017;18(5):654–662. [CrossRef] [PubMed] [Google Scholar]
  20. Lescaille G, Lang P, Ernenwein D, Javelot MJ, Descroix V. Intérêt de la photothérapie au laser pour le traitement des mucites de la cavité buccale. Présentation d'un cas et revue de la littérature. Med Buccale Chir Buccale 2010;16:171–176. [CrossRef] [Google Scholar]
  21. Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M, et al. Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 1999;7(4):244–252. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.